• Publications
  • Influence
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of
### A. Definition, classification, and mechanisms of toxicity Cardiac dysfunction resulting from exposure to cancer therapeutics was first recognized in the 1960s, with the widespread introductionExpand
  • 823
  • 86
  • PDF
Congestive heart failure in patients treated with doxorubicin
Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug. A large‐scale study thatExpand
  • 1,358
  • 48
  • PDF
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth
PURPOSE The objective of this study was to determine whether the addition of trastuzumab to chemotherapy in the neoadjuvant setting could increase pathologic complete response (pCR) rate in patientsExpand
  • 1,021
  • 34
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human
PURPOSE Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or afterExpand
  • 717
  • 27
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
  • M. Ewer, S. Lippman
  • Medicine
  • Journal of clinical oncology : official journal…
  • 1 May 2005
Cancer chemotherapy can affect the heart in a variety of ways. Fluorouracil and capecitabine may initiate coronary artery spasm, high-dose cyclophosphamide can induce a hemorrhagic myonecrosis, andExpand
  • 503
  • 23
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
PURPOSE Trastuzumab is an important biologic agent with significant activity in breast cancers that overexpress the HER2/neu marker. However, trastuzumab is associated with cardiotoxicity that hasExpand
  • 595
  • 22
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survivalExpand
  • 405
  • 15
Cancer drugs and the heart: importance and management.
Progress in the detection and treatment of cancer has led to an impressive reduction in both mortality and morbidity. Due to their mechanism of action, however, conventional chemotherapeutics andExpand
  • 292
  • 15
  • PDF
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factorsExpand
  • 697
  • 13
  • PDF
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti‐cancer agentsExpand
  • 324
  • 13